Seven-years post allogeneic hematopoietic stem cell transplantation pure red cell aplastic anemia cured with daratumumab: A case report and review of literature

Figure 1 Treatment process of pure red cell aplastic anaemia patients after unrelated human leukocyte antigen-matched AB + /O + allo-transplantation. Hemoglobin (Y axis), transplant days (X axis), absolute value of reticulocyte, frequency of red blood cell infusion, and changes in blood type before and after transplantation are shown here, and the trend of treatment with plasmapheresis, interferon, mesenchymal stem cells, and Daratumumab (shaded) is shown. Red blood cell transfusion frequency showed no change before and after plasmapheresis, interferon, and mesenchymal stem cell treatment, but after 5 dosages of Daratumumab, hemoglobin significantly increased, red blood cell transfusion frequency decreased.